Brilaroxazine, developed by Reviva Therapeutics, exhibits potent affinity and selectivity against key serotonin and dopamine receptors implicated in schizophrenia.
Brilaroxazine’s pharmacological profile sets it apart from traditional antipsychotics. Operating as a partial agonist at D2/3/4 and 5-HT1A/2A receptors and an antagonist at 5-HT2B/7 receptors, it offers a multifaceted mechanism of action.
One of the most promising aspects of Brilaroxazine is its tolerability profile. Clinical data indicate that the drug exhibits a generally well-tolerated side effect profile comparable to placebo, with lower discontinuation rates.
Reviva Therapeutics’ lead candid...
